万邦德: 简式权益变动报告书（万邦德集团及其一致行动人）

Core Viewpoint - The report outlines a share transfer agreement involving Wanbangde Pharmaceutical Holdings Group Co., Ltd., where a total of 60,000,000 shares, representing 9.8089% of the company's total equity, will be transferred to Wenzhou Wanlong Pharmaceutical Technology Partnership (Limited Partnership) through a private agreement [1][9]. Group 1: Shareholding Changes - Prior to the transfer, the information disclosing parties collectively held 308,747,078 shares, accounting for 50.4745% of the total equity of the company [7]. - After the transfer, the shareholding of the information disclosing parties will decrease to 248,747,078 shares, representing 40.6656% of the total equity [7]. - The specific shareholding changes include Wanbangde Group reducing its shares from 193,426,693 (31.6217%) to 176,387,367 (28.8361%), Zhao Shouming from 49,677,267 (8.1213%) to 37,267,267 (6.0925%), and others accordingly [7]. Group 2: Share Transfer Agreement Details - The share transfer agreement specifies that the shares will be sold at a price of 6.88 RMB per share, totaling 412,800,000 RMB for the entire transaction [9][10]. - The agreement outlines that the transfer will be executed within five trading days after obtaining the necessary confirmations from the Shenzhen Stock Exchange [10]. - The parties involved in the transfer include Wanbangde Group, Zhao Shouming, and others, with the receiving party being Wenzhou Wanlong Pharmaceutical [9][10]. Group 3: Compliance and Future Plans - The share transfer is subject to compliance confirmation and registration procedures with the Shenzhen Securities Registration and Settlement Company [2][11]. - As of the report date, the information disclosing parties have no plans to increase or further reduce their shareholding in the company within the next 12 months [5][14]. - The report confirms that there are no outstanding debts or guarantees that could harm the interests of the company or its shareholders related to the share transfer [15].